Sage Therapeutics has said it will cut its headcount ... whose responsibilities will be taken over by chief medical officer Laura Gault. Head of medical affairs Mark Pollack is also stepping ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Sage Therapeutics stock opened at $7.44 on Friday. The business’s 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.53. The stock has a market cap of $455.13 ...

On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Biogen proposed acquiring Sage Therapeutics for $7.22 per share; Sage stock has dropped 90% in five years. Sage reorganized in October, cutting 165+ jobs and shifting focus to Zurzuvae for ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. (Nasdaq: SAGE) has received an acquisition offer from its longtime partner. After a 2024 marred by a series of trial ...